Advertisement

Potential Genetic Causes of Heterogeneity of Treatment Effects

      Abstract

      Nongenetic biologic and lifestyle-related factors, including age, sex, hepatic/renal function, diet/exercise practices, illness severity, smoking, and alcohol consumption habits can account for the heterogeneity of treatment effects (HTE). However, even when these factors are taken into account, considerable variation remains unexplained and could potentially be attributable to genetic differences between patients. Drug response may be dictated by variation in genes involved in both pharmacokinetic (PK) (absorption, distribution, metabolism, excretion [ADME]) and pharmacodynamic (PD) (receptors, ion channels, enzymes, immune system) pathways. Functional variants of the ADME genes can result in patients being poor, intermediate, efficient, or ultrarapid metabolizers of specific agents, thereby affecting efficacy and/or susceptibility to adverse drug reaction and necessitating individualized dosing. A well-documented example of ADME gene variation is the debrisoquine polymorphism, which is characterized by markedly different metabolism of numerous commonly prescribed drugs based on variants of the cytochrome P450 2D6 gene. Variants of genes regulating PD pathways cause altering of drug target pathways, which may affect efficacy in a more pronounced manner. Examples of gene variants affecting PD pathways include those coding for dopamine metabolism, synthesis, and transport. These gene variants may act independently, in combination with each other, and/or in combination with PK genes to affect drug response, for example to antipsychotic medications. Increased understanding of a patient’s genotype and its corresponding effect on drug response would be useful to the practicing clinician in choosing an effective drug and in optimizing the dose in a timely manner.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Spear B.B.
        • Heath-Chiozzi M.
        • Huff J.
        Clinical application of pharmacogenetics.
        Trends Mol Med. 2001; 7: 201-204
        • Greenfield S.
        • Kravitz R.
        • Duan N.
        • Kaplan S.H.
        Heterogeneity of treatment effects: implications for guidelines, payment and quality assessment.
        Am J Med. 2007; 120: S3-S9
        • Fritz N.
        • Glogau S.
        • Hoffmann J.
        • et al.
        Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy.
        Epilepsy Behav. 2005; 6: 373-381
        • Kockelmann E.
        • Elger C.E.
        • Helmstaedter C.
        Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients.
        Epilepsy Res. 2003; 54: 171-178
        • Lee S.
        • Sziklas V.
        • Andermann F.
        • et al.
        The effects of adjunctive topiramate on cognitive function in patients with epilepsy.
        Epilepsia. 2003; 44: 339-347
        • Rorsman I.
        • Kallen K.
        Recovery of cognitive and emotional functioning following withdrawal of topiramate maintenance therapy.
        Seizure. 2001; 10: 592-595
        • Thompson P.J.
        • Baxendale S.A.
        • Duncan J.S.
        • Sander J.W.
        Effects of topiramate on cognitive function.
        J Neurol Neurosurg Psychiatry. 2000; 69: 636-641
        • Han S.W.
        • Kim T.Y.
        • Jeon Y.K.
        • et al.
        Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
        Clin Cancer Res. 2006; 12: 2538-2544
        • Hamelin B.A.
        • Turgeon J.
        • Vallee F.
        • et al.
        The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin.
        Clin Pharmacol Ther. 1996; 60: 512-521
        • Ereshefsky L.
        • Riesenman C.
        • Lam Y.W.
        Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6.
        Clin Pharmacokinet. 1995; 29: 10-18
        • Brosen K.
        The pharmacogenetics of the selective serotonin reuptake inhibitors.
        Clin Investig. 1993; 71: 1002-1009
        • Eap C.B.
        • Bondolfi G.
        • Zullino D.
        • et al.
        Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.
        J Clin Psychopharmacol. 2001; 21: 330-334
        • Whyte E.M.
        • Romkes M.
        • Mulsant B.H.
        • et al.
        CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
        Int J Geriatr Psychiatry. 2006; 21: 746-751
        • Steimer W.
        • Zopf K.
        • von Amelunxen S.
        • et al.
        Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
        Clin Chem. 2004; 50: 1623-1633
        • Steimer W.
        • Zopf K.
        • von Amelunxen S.
        • et al.
        Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
        Clin Chem. 2005; 51: 376-385
        • Ingelman-Sundberg M.
        Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
        Pharmacogenomics J. 2005; 5: 6-13
        • Kirchheiner J.
        • Nickchen K.
        • Bauer M.
        • et al.
        Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
        Mol Psychiatry. 2004; 9: 442-473
        • Rogowski W.
        Current impact of gene technology on healthcare: a map of economic assessments.
        Health Policy. 2007; 80: 340-357
        • Need A.C.
        • Motulsky A.G.
        • Goldstein D.B.
        Priorities and standards in pharmacogenetic research.
        Nat Genet. 2005; 37: 671-681
        • Bradford L.D.
        CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.
        Pharmacogenomics. 2002; 3: 229-243
        • Johansson I.
        • Oscarson M.
        • Yue Q.Y.
        • et al.
        Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
        Mol Pharmacol. 1994; 46: 452-459
        • Masimirembwa C.
        • Persson I.
        • Bertilsson L.
        • Hasler J.
        • Ingelman-Sundberg M.
        A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.
        Br J Clin Pharmacol. 1996; 42: 713-719
        • Tate S.K.
        • Goldstein D.B.
        Will tomorrow’s medicines work for everyone?.
        Nat Genet. 2004; 36: S34-S42
        • Bakker P.R.
        • van Harten P.N.
        • van Os J.
        Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
        Schizophr Res. 2006; 83: 185-192
        • Bertolino A.
        • Caforio G.
        • Blasi G.
        • et al.
        Interaction of COMT (Val108/158 Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.
        Am J Psychiatry. 2004; 161: 1798-1805
        • Hedenmalm K.
        • Guzey C.
        • Dahl M.L.
        • Yue Q.Y.
        • Spigset O.
        Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
        J Clin Psychopharmacol. 2006; 26: 192-197
        • Matsumoto C.
        • Shinkai T.
        • De Luca V.
        • et al.
        Association between three functional polymorphisms of the dopamine D2 receptor gene and polydipsia in schizophrenia.
        Int J Neuropsychopharmacol. 2005; 8: 245-253
        • Zhao A.L.
        • Zhao J.P.
        • Zhang Y.H.
        • et al.
        Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine.
        Int J Neurosci. 2005; 115: 1539-1547
        • Arinami T.
        • Gao M.
        • Hamaguchi H.
        • Toru M.
        A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.
        Hum Mol Genet. 1997; 6: 577-582
        • Contini V.
        • Marques F.Z.
        • Garcia C.E.
        • Hutz M.H.
        • Bau C.H.
        MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence.
        Am J Med Genet B Neuropsychiatr Genet. 2006; 141: 305-308
        • Garpenstrand H.
        • Ekblom J.
        • Forslund K.
        • Rylander G.
        • Oreland L.
        Platelet monoamine oxidase activity is related to MAOB intron 13 genotype.
        J Neural Transm. 2000; 107: 523-530
        • Heinz A.
        • Goldman D.
        • Jones D.W.
        • et al.
        Genotype influences in vivo dopamine transporter availability in human striatum.
        Neuropsychopharmacology. 2000; 22: 133-139
        • Syvanen A.C.
        • Tilgmann C.
        • Rinne J.
        • Ulmanen I.
        Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland.
        Pharmacogenetics. 1997; 7: 65-71
        • Wei J.
        • Ramchand C.N.
        • Hemmings G.P.
        Possible association of catecholamine turnover with the polymorphic (TCAT)n repeat in the first intron of the human tyrosine hydroxylase gene.
        Life Sci. 1997; 61: 1341-1347
        • Need A.C.
        • Ahmadi K.R.
        • Spector T.D.
        • Goldstein D.B.
        Obesity is associated with genetic variants that alter dopamine availability.
        Ann Hum Genet. 2006; 70: 293-303
        • Sconce E.A.
        • Khan T.I.
        • Wynne H.A.
        • et al.
        The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
        Blood. 2005; 106: 2329-2333
        • Ahmadi K.R.
        • Weale M.E.
        • Xue Z.Y.
        • et al.
        A single-nucleotide polymorphism tagging set for human drug metabolism and transport.
        Nat Genet. 2005; 37: 84-89
        • Shah P.R.
        • hmad-Annuar A.
        • Ahmadi K.R.
        • et al.
        No association of DYNC1H1 with sporadic ALS in a case-control study of a northern European derived population: a tagging SNP approach.
        Amyotroph Lateral Scler Other Motor Neuron Disord. 2006; 7: 46-56
        • Shephard N.
        • John S.
        • Cardon L.
        • McCarthy M.I.
        • Zeggini E.
        Will the real disease gene please stand up?.
        BMC Genet. 2005; 6: S66